

Visual impairment and frailty: insight from genetic correlation and Mendelian randomization

Keywords

causal relationship, visual impairment, frailty, Mendelian randomization, linkage disequilibrium score regression

Abstract

Introduction

Visual impairment (VI) is associated with frailty in observational studies, but whether this relationship is causal remains uncertain. This study aimed to investigate the genetic correlation and causal associations between genetically predicted VI and frailty using Mendelian randomization (MR) and linkage disequilibrium score regression (LDSC).

Material and methods

Genome-wide association studies provided summary data for VI subtypes (glaucoma, cataracts, diabetic retinopathy, age-related macular degeneration, hypermetropia, myopia) and frailty measures (Frailty Index (FI) and Fried Frailty Score (FFS)). LDSC was used to estimate genetic correlations, and MR was conducted using inverse-variance weighted (IVW) as the primary method, supplemented by MR-Egger and weighted median. Sensitivity analyses, including Radial MR, Cochran's Q test, MR-Egger intercept, and MR-PRESSO, assessed pleiotropy and heterogeneity.

Results

Significant genetic correlations were found between VI, cataracts, age-related macular degeneration, and frailty. Suggestive correlations were identified between myopia and FI. MR analysis showed increased FI and FFS risks with other cataracts (FI: $P = 0.0324$; FFS: $P = 0.027$) and diabetic retinopathy (FI: $P < 0.001$; FFS: $P = 0.0119$). Visual disturbances were linked to increased FI risk ($P = 0.0101$), while age-related macular degeneration elevated FFS risk ($P = 0.0251$). Reverse analysis revealed frailty also increased susceptibility to VI. No causal relationships were found for other eye diseases, and analyses showed no evidence of pleiotropy or heterogeneity.

Conclusions

This study highlights significant genetic links and bidirectional causal relationships between VI and frailty. Future research should include multiethnic populations and larger datasets to further explore these mechanisms.

1 **Visual impairment and frailty: insight from genetic** 2 **correlation and Mendelian randomization**

3 Zhen Deng^{1,2}, Ziding Buyang², Tianshu Hou^{1*}

4 1. Chengdu Integrated Traditional Chinese Medicine and Western Medicine Hospital,
5 Chengdu, China

6 2. Chengdu University of Traditional Chinese Medicine, Chengdu, China

7 *Correspondence: Tianshu Hou, houtianshu@cdutcm.edu.cn

8 **Abstract**

9 **Introduction:** Visual impairment (VI) is associated with frailty in observational studies, but whether
10 this relationship is causal remains uncertain. This study aimed to investigate the genetic correlation
11 and causal associations between genetically predicted VI and frailty using Mendelian randomization
12 (MR) and linkage disequilibrium score regression (LDSC).

13 **Method:** Genome-wide association studies provided summary data for VI subtypes (glaucoma,
14 cataracts, diabetic retinopathy, age-related macular degeneration, hypermetropia, myopia) and frailty
15 measures (Frailty Index (FI) and Fried Frailty Score (FFS)). LDSC was used to estimate genetic
16 correlations, and MR was conducted using inverse-variance weighted (IVW) as the primary method,
17 supplemented by MR-Egger and weighted median. Sensitivity analyses, including Radial MR,
18 Cochran's Q test, MR-Egger intercept, and MR-PRESSO, assessed pleiotropy and heterogeneity.

19 **Results:** Significant genetic correlations were found between VI, cataracts, age-related macular
20 degeneration, and frailty. Suggestive correlations were identified between myopia and FI. MR
21 analysis showed increased FI and FFS risks with other cataracts (FI: $P = 0.0324$; FFS: $P = 0.027$) and
22 diabetic retinopathy (FI: $P < 0.001$; FFS: $P = 0.0119$). Visual disturbances were linked to increased
23 FI risk ($P = 0.0101$), while age-related macular degeneration elevated FFS risk ($P = 0.0251$). Reverse
24 analysis revealed frailty also increased susceptibility to VI. No causal relationships were found for
25 other eye diseases, and analyses showed no evidence of pleiotropy or heterogeneity.

26 **Conclusion:** This study highlights significant genetic links and bidirectional causal relationships
27 between VI and frailty. Future research should include multiethnic populations and larger datasets to
28 further explore these mechanisms.

29 **Keywords:** visual impairment, frailty, Mendelian randomization, causal relationship, linkage
30 disequilibrium score regression.

31 **Introduction**

32 Visual impairment (VI) is prevalent among the elderly population. Approximately 3.22 million
33 individuals in the United States experience vision impairment, with the highest proportion (50%)
34 being elderly persons aged 80 years and older 1. VI has a detrimental impact on all elements of
35 everyday living, including physical and cognitive abilities 2-4. It is also linked to the possibility of
36 disability, comorbidity, and death 5,6. In high-income countries, the main causes of VI in older
37 individuals are uncorrected refractive errors, diabetic retinopathy, cataracts, and glaucoma, with age-
38 related macular degeneration being the leading cause of blindness 7.

39 Frailty is characterized by increased vulnerability to health problems due to declining bodily reserves
40 and physiological dysfunction, often associated with aging 8. Likewise, elderly individuals who are

41 weak face the possibility of experiencing negative health outcomes such as falls 9, incapacity 10,
42 hospitalization 11, and even death 11. A recent comprehensive investigation, which included 62
43 nations and regions, revealed that the overall occurrence of physical frailty among older people was
44 12% 12. Furthermore, frailty exacerbates the financial burden of healthcare for elderly individuals
45 13.

46 As frailty is a major risk factor for disability and VI is linked to functional decline, studying their
47 relationship is crucial. A cross-sectional study of 2962 people over the age of 43 found that poorer
48 visual acuity and contrast sensitivity were associated with lower frailty scores 14. VI has also been
49 linked to an increased risk of frailty and its progression 15. In addition, Gonzales-Turin et al.'s study
50 1 showed that VI was shown to be positively associated with frailty in older non-frail, pre-frail, and
51 robust adults. After correcting for propensity scores, Varadaraj et al. 16 discovered a substantial
52 relationship between near vision impairment and frailty. Swenor et al. 6 discovered that fragility is
53 strongly linked with VI severity.

54 Nevertheless, it is important to acknowledge that the findings regarding the correlation between VI
55 and frailty are inconclusive. The majority of research has seen an association between VI and frailty,
56 whereas a small number of studies did not find any relationship 17,18. Due to the restriction of
57 observational studies, it remains uncertain if there is a causal association between VI and frailty.
58 Hence, further investigation into the causal correlation between the two phenomena is required.


59 Recent studies have used genome-wide association studies (GWAS) to estimate trait correlations and
60 causality. Linkage disequilibrium score regression (LDSC) leverages GWAS summary statistics to
61 assess genetic associations 19. Mendelian randomization (MR) infers causal relationships between
62 variables using genetic variation 20. Genotype precedes phenotype, and alleles are randomly
63 allocated at conception; therefore, genetic variation may be used to evaluate causality without reverse

64 causality interference or confounding bias 21,22. This study thus investigated causal relationships
65 and the genetic correlation between genetically predicted VI and frailty using MR and LDSC.

66 **Methods**

67 **Study Design**

68 This study adheres to the STROBE Statement 23. The study flowchart is shown in Figure 1. This
69 study employed a bidirectional MR approach to identify potential causal relationships while avoiding
70 false-negative causality 24. In order to guarantee effective causal reasoning in MR research, three
71 prerequisites must be fulfilled: (1) genetic instrumental variables (IVs) with strong associations to
72 exposure; (2) genetic IVs are independent of potential confounding variables.; and (3) specific
73 genetic IVs are influenced by exposures while other factors are not 25.



74

75 Figure 1. The study design of our investigation. IVs, instrumental variables; MR, mendelian
 76 randomization; IVW, inverse-variance weighted.

77 **Data sources**

78 **Exposure**

79 The FinnGen Consortium is an ongoing genetic research project that combines genetic data from the
 80 Finnish Biobank with digital health records from the Finnish Health Registry (FinnGen, 1985). The
 81 FinnGen project used Illumina and Affymetrix arrays for genotyping, with strong quality control
 82 protocols in place. The published study 26 includes detailed participant information, genotyping
 83 processes, and quality control measures. We used GWAS data from Finland (R11) for VI and related

84 eye diseases as exposure data (<https://finngen.gitbook.io/documentation/>). These data include visual
85 disturbances, glaucoma, senile cataracts, other cataracts, diabetic retinopathy, age-related macular
86 degeneration, hypermetropia, and myopia.

87 **Outcome**

88 From the GWAS catalog, we retrieved GWAS summary statistics for the frailty index. The frailty
89 index (FI) was used to assess frailty in a study of 175,226 people of European heritage, including
90 164,610 UK Biobank participants aged 60- 70 and 10,616 Swedish TwinGene participants aged 41-
91 87 years 27. FI incorporates dozens of factors, including symptoms, indicators, disease state, and
92 disability, to depict the accumulation of possible health losses over a lifetime. According to the UK
93 Biobank and TwinGene defect accumulation theories, FI was estimated using 49 or 44 self-reported
94 items, respectively 27.

95 The UK Biobank provided summary-level information for the Fried frailty score (FFS), including a
96 number of 386,565 people 28. Depending on how many of the criteria (weight loss, tiredness, poor
97 physical activity, slow gait speed, and weak grip strength) were met, participants were given an FFS
98 score ranging from 0 to 5.

99 There is debate over the definition and assessment of frailty, but the two most commonly used tools
100 are the FI and FFS. In terms of determinants and frailty identification, the FI and FFS show
101 convergence while having different conceptual foundations 29. FI is predicated on the cumulative
102 deficit concept, which quantifies the ratio of health deficiencies, encompassing symptoms, diseases,
103 and functional impairments. It offers a thorough multidimensional assessment of frailty, appropriate
104 for analyzing long-term effects, however it necessitates substantial data gathering. Conversely, FFS
105 relies on a biological framework encompassing five criteria (unintentional weight loss, diminished
106 grip strength, weariness, reduced physical activity, and decreased walking speed) and categorizes

107 frailty into three classifications. It is more straightforward and pragmatic for fast assessment,
 108 although less responsive to nuanced health variations. All the data are shown in Table 1 and Table 2.
 109 All research participants were of European ethnicity, and there was no sample overlap in the
 110 exposure and outcome data.

111 Table 1. Information on the data source for VI.

Phenotype	Data source	ID	Number of cases	Number of controls	Ancestry
Visual disturbances	Finngen	H7_VISUDISTURB	19780	432149	European
Glaucoma	Finngen	H7_GLAUCOMA	23483	430250	European
Senile cataracts	Finngen	H7_CATARACTSENILE	73410	374263	European
Other cataracts	Finngen	H7_CATARACTOTHER	22118	374263	European
Diabetic retinopathy	Finngen	DM_RETINOPATHY	12681	71596	European
Age-related macular degeneration	Finngen	H7_AMD	11023	419198	European
Hypermetropia	Finngen	H7_HYPERMETRO	2338	432955	European
Myopia	Finngen	H7_MYOPIA	4732	432955	European

112

113 Table 2. Information on the data source for frailty.

Phenotype	Data source	GWAS ID	PMID	Sample size	Ancestry
Frailty index	UK Biobank and TwinGene	ebi-a-GCST90020053	34431594	N=175226	European

114

115 Instrumental variables selection

116 We screened genetic IVs using the following criteria: (1) SNPs significantly linked to exposure and
117 outcome at the genome-wide level ($P < 5 \times 10^{-8}$). However, due to the low number of IVs that meet
118 the threshold ($P < 5 \times 10^{-8}$), a wider criteria ($P < 5 \times 10^{-6}$) was used in partial exposures. The choice
119 to lower the threshold in the IV screening procedure was predicated on the necessity to reconcile
120 statistical power with validity. The standard criterion ($P < 5 \times 10^{-8}$) is frequently employed to
121 discern reliable genetic instruments in Mendelian randomization research. Nonetheless, this rigorous
122 criterion frequently leads to a restricted quantity of instrumental variables, particularly in datasets
123 with small sample sizes or when examining traits with feeble genetic signals. By lowering the criteria
124 to $P < 5 \times 10^{-6}$, we sought to incorporate supplementary genetic variants that could augment the
125 explanatory capacity of the IVs while preserving an acceptable degree of validity 24,30. (2) Using a
126 clumping approach ($R^2 < 0.001$, window size = 10,000 kb), we were able to guarantee each SNP's
127 independence and eliminate variations with strong linkage disequilibrium (LD). (3) SNPs with a
128 minor allele frequency less than 0.01, SNPs with non-concordant alleles, and SNPs with palindromic
129 sequences were removed from the analysis. (4) We searched the GWAS Catalog
130 (<https://www.ebi.ac.uk/gwas/>) for secondary phenotypes of each SNP in order to rule out the
131 possibility of pleiotropic effects. SNPs linked to the characteristic of interest were eliminated, and the
132 remaining SNPs were used in later studies. (5) We evaluated each SNP's statistical efficacy using the
133 F-statistic ($F = \beta^2/se^2$) 31 and removed any SNPs with low efficacy to reduce minor instrumental bias
134 ($F > 10$). In addition, if the dataset for outcomes did not contain particular SNPs related to exposures,
135 we excluded them and did not utilize proxy SNPs as replacements.

136 **Mendelian randomization analysis**

137 MR-Egger, inverse-variance weighted (IVW), and weighted median were among the complementary
138 methodologies that we implemented. In our extensive samples, we employed the IVW approach to
139 assess the causative relationship between frailty and VI. We believed that the IVW method was the
140 most effective method for assessing causal effects due to our extensive exposure to IVs 32. As a
141 result, the IVW approach was the primary method of analysis for MR. The MR impact magnitude
142 was estimated using random-effect IVW when IVs exhibited significant heterogeneity ($P < 0.05$).
143 Fixed-effect IVW was implemented when it was absent 33.

144 **Sensitivity analysis**

145 In order to evaluate the robustness of the findings, we conducted numerous sensitivity analyses. The
146 Cochran Q test 34, which encompasses the MR-egger and inverse variance weighted methodologies,
147 was implemented to assess heterogeneity. Furthermore, the horizontal pleiotropy was evaluated using
148 the MR-Egger intercept 35. On the other hand, MR-PRESSO packages 36 and Radial MR programs
149 37 are employed to identify heterogeneous SNPs and exclude them from the final analysis.
150 Additionally, the leave-one-out test 38 was implemented to determine the stability of these causal
151 estimates.

152 RStudio (version 4.2.2) was employed in conjunction with the packages "TwoSampleMR" (version
153 0.6.6), "Radial MR" (version 1.0), and MRPRESSO" (version 1.0) to conduct the comprehensive
154 analysis.

155 **Linkage disequilibrium score (LDSC) regression analysis**

156 Using LDSC, we calculated the genetic correlation (r_g) between frailty and VI. LDSC regression
157 analysis is an efficient and dependable method for determining the genetic frameworks underlying

158 complex human phenotypes 39. To estimate the inflationary effect of a real polygenic signal or bias,
159 the LDSC looks at the relationship between test statistics and linkage disequilibrium 40. This
160 approach is not influenced by sample overlap and may assess genetic association using GWAS
161 summary data 19. For our study, the researchers created an LD reference panel using 1000 genomes
162 (source: <https://github.com/bulik/ldsc>) and European LD scores. It was determined that $P < 0.003125$
163 ($0.05/8*2$, following stringent Bonferroni correction) was statistically significant. It was determined
164 that $0.003125 < P < 0.05$ indicated a possible genetic link.

165 **Results**


166 **Instrumental variables**

167 During the initial IV screening process, if the number of IVs was less than 10, then we relaxed the
168 threshold ($P < 5 \times 10^{-6}$). Therefore, we relaxed the thresholds for visual disturbances, hypermetropia,
169 and myopia ($P < 5 \times 10^{-6}$). We identified 6 to 43 SNPs as IVs for the outcomes of VI and frailty,
170 respectively, after conducting a thorough screening process (Figures 2 and 3). Since heterogeneity
171 was not detected by the Cochran's Q test ($P > 0.05$), we used the IVW technique to create a fixed-
172 effects model. The F-statistics, all of which are more than 10, demonstrate that there is no marginal
173 instrumental bias. IVs information and F-value results are visible in Supplementary material 2.

174 **Causal effect of VI on frailty**

175 Figure 2 presents the results of the estimation of the causal relationship between VI and the two
176 frailty characteristics. Applying the IVW approach, we found that other types of cataract (FI: $P =$
177 0.0324 , OR = 1.03; 95% CI = 1.00–1.05; FFS: $P = 0.027$, OR = 1.01; 95% CI = 1.00–1.03) and
178 diabetic retinopathy (FI: $P < 0.001$, OR = 1.04; 95% CI = 1.03–1.06; FFS: $P = 0.0119$, OR = 1.02;
179 95% CI = 1.01–1.02) were associated with an increased risk of frailty. And this risk was seen in both

180 FI and FFS. However, there is an increased risk of FI associated with visual disturbances ($P =$
 181 0.0101 , $OR = 1.04$; $95\% CI = 1.01-1.07$), which appears to be less sensitive in FFS. In addition, age-
 182 related macular degeneration was only significant in the increased risk of FFS ($P = 0.0251$, $OR =$
 183 1.01 ; $95\% CI = 1.00-1.01$).




184

185 Figure 2: MR analysis for VI on frailty index. nSNP, quantity of SNPs employed in MR; OR, odds
 186 ratio.

187 Causal effect of frailty on VI

188 In the reverse analysis (Figure 3), we found evidence that FI ($P = 0.00165$, $OR = 1.60$; $95\% CI =$
 189 $1.19-2.15$) and FFS ($P = 0.015$, $OR = 1.60$; $95\% CI = 1.10-2.34$) are associated with an increased
 190 risk of VI. Surprisingly, the susceptibility to VI in frail patients does not seem to manifest itself in the
 191 other seven VI characteristics, which suggests that frailty does not affect VI through these pathways.



192

193 Figure 3: MR analysis for frailty on VI. nSNP, quantity of SNPs employed in MR; OR, odds ratio;
 194 CI.

195 Sensitivity analyses

196 Our research found no substantial indication of horizontal pleiotropy in these results, indicating that
 197 the IVs employed in this study were not influenced by any variables other than the exposures being
 198 examined. The durability of the results was evaluated by the utilization of Cochran's Q test, MR-
 199 PRESSO, and the MR-Egger intercept test. The findings of each sensitivity analysis are shown in
 200 Supplementary material 1.

201 LDSC

202 We used LDSC regression analysis to evaluate the genetic associations between eight visually
 203 impaired features and two assessments of frailty. Table 3 demonstrates that our research reveals

204 significant genetic relationships among visual disturbances, cataracts, age-related macular
 205 degeneration, and frailty. Among these, there is no genetic association between senile cataract and
 206 FFS. Furthermore, there is a suggestive genetic link between myopia and FI.

207 Table 3. Results of LDSC between VI and frailty.

Exposure	Outcome	rg	rg_se	rg_p
Visual disturbances	Frailty index	0.50	0.07	<0.001
	Fried Frailty Score	0.35	0.06	<0.001
Glaucoma	Frailty index	0.03	0.03	0.232
	Fried Frailty Score	-0.01	0.03	0.681
Senile cataract	Frailty index	0.25	0.03	<0.001
	Fried Frailty Score	0.04	0.04	0.356
Other cataract	Frailty index	0.22	0.04	<0.001
	Fried Frailty Score	0.17	0.04	<0.001
Diabetic retinopathy	Frailty index	-0.03	0.07	0.716
	Fried Frailty Score	-0.04	0.07	0.562
Age-related macular degeneration	Frailty index	0.19	0.04	<0.001
	Fried Frailty Score	0.18	0.04	<0.001
Hypermetropia	Frailty index	0.10	0.08	0.188
	Fried Frailty Score	<0.01	0.07	0.963
Myopia	Frailty index	0.11	0.04	0.0125
	Fried Frailty Score	0.04	0.04	0.356

208 **Discussion**

209 This study is the first to investigate the genetic connection and probable causation between VI and
210 frailty using GWAS summary statistics. The results of our study indicate strong genetic associations
211 between visual disturbances, cataract, age-related macular degeneration, and frailty. There were
212 indications of genetic links between Myopia and FI. In addition, our MR analysis revealed evidence
213 of a causal relationship between several VI traits and frailty. These findings will facilitate our
214 continued investigation into the correlation between VI and the aging process. Furthermore, it offers
215 novel insights into the potential processes behind the initiation and progression of frailty. These
216 methods are commonly used in genetic epidemiology to examine causal relationships and genetic
217 correlations. Other tools, such as polygenic risk scores (PRS) and gene-environment interaction
218 models, could further enhance the understanding of the complex genetic architecture of frailty and
219 visual impairments.

220 Our results align with most existing literature, which shows that VI is linked to higher frailty. A long-
221 term study of older adults found that those with VI were more prone to frailty than those without it,
222 demonstrating a temporal relationship 8. Other studies also suggest that VI in the elderly can lead to
223 severe health problems 15. Participants with VI but no frailty had twice the risk of developing frailty
224 later, compared to those without either VI or frailty, even after adjusting for other factors 15.

225 Several mechanisms may explain the link between VI and frailty. In age-related muscle atrophy,
226 sarcopenia, oxidative stress, chronic inflammation, and mitochondrial dysfunction play significant
227 roles in frailty 41. Chronic inflammation is a known cause of visual abnormalities, and older
228 individuals with VI often experience higher oxidative stress levels 42,43. Additionally, mitochondrial
229 dysfunction and disorders are associated with VI. Severe VI is also linked to a higher prevalence of
230 sarcopenia and frailty 45.

231 A vicious cycle may exist between VI and frailty. Frailty-related comorbidities such as diabetes and
232 cardiovascular disease are associated with VI 46. Moreover, both VI and frailty are connected to
233 similar pathological processes, including inflammation 47. Additionally, frail elderly individuals are
234 at risk of social isolation due to reduced activity, which has been linked to VI 8,48. These factors
235 may interact to create a harmful cycle.

236 This study found genetic correlations between some visual impairments and frailty but no significant
237 causal relationships for others, such as hypermetropia or glaucoma. There are several possible
238 explanations for these findings. Specific visual impairments like glaucoma might influence frailty
239 indirectly through processes like neurodegeneration, rather than directly affecting frailty-associated
240 features. Also, our study primarily includes data from European populations, which may limit the
241 ability to identify links for certain illnesses due to a lack of genetic diversity. Ultimately, variations in
242 frailty definitions and instruments (FI vs FFS) may affect sensitivity to correlations⁴⁹. FI and FFS
243 are two widely used tools for assessing frailty, but they differ significantly in their approach. FI is
244 based on the cumulative deficit model, which quantifies the ratio of health deficiencies,
245 encompassing a wide range of symptoms, diseases, and functional impairments. This makes it a
246 comprehensive and multidimensional assessment tool, ideal for evaluating long-term frailty
247 progression. However, it requires substantial data gathering and is sensitive to subtle health
248 variations. In contrast, FFS is based on a biological framework that assesses five physical criteria:
249 unintentional weight loss, diminished grip strength, fatigue, reduced physical activity, and slow gait
250 speed 50. FFS is typically used for quick assessments of frailty, categorizing individuals into three
251 groups based on the number of criteria met. The differences in the scope and sensitivity of these tools
252 may influence the observed relationship between frailty and visual impairment, with FI offering a
253 broader and potentially more nuanced assessment.

254 This work identifies genetic links and causal relationships between specific visual impairments (such
255 as cataracts and diabetic retinopathy) and frailty, which have clinical significance. Early
256 identification and intervention for treatable visual impairments, like cataracts or diabetic retinopathy,
257 may help reduce the risk of frailty in older individuals, improving their quality of life and autonomy.
258 Ophthalmologists may consider frailty screening for visually impaired individuals. Secondly,
259 multidisciplinary treatments aimed at at-risk persons (e.g., coordinated care between
260 ophthalmologists and geriatricians) may assist in delaying or preventing the advancement of frailty.
261 Healthcare professionals may send elderly patients who are frail or have vision impairments to
262 ophthalmologists. By using medication or surgery to address treatable VI, frailty may be reduced.
263 Both vulnerable individuals and future screening standards will benefit from this. Furthermore, these
264 findings underscore the necessity of regular visual function evaluations in frail individuals, as visual
265 impairment may constitute an overlooked risk factor for frailty. Interventions targeting visual
266 impairments may indirectly enhance frailty status and reduce associated negative outcomes,
267 including falls, hospitalizations, and early mortality.

268 In spite of this, our investigation has some limitations. The GWAS data that we initially employed
269 was primarily sourced from individuals of European descent. This focus on a homogeneous
270 population limits the generalizability of our findings to other ethnic groups. Future studies should
271 include more diverse populations to evaluate the consistency of the association between visual
272 impairment and frailty across different racial and ethnic subgroups. Second, we only incorporated the
273 eight most prevalent VI features due to the constraints of the non-overlapping samples and available
274 IVs. Comprehensive data analysis is required to conduct a thorough examination of the relationship
275 between frailty and VI. Third, we note that there are differences in the results obtained for different
276 definitions of frailty. We believe this is due to the VI influence pathway, which helps us explore the
277 mechanisms involved. A more thorough structural analysis of frailty is therefore required to reveal

278 the critical mechanisms that link frailty and VI. Finally, due to technical and data limitations, we
279 could not conduct subgroup analyses by age, sex, or severity. Future research should include more
280 diverse populations to assess how the relationship between visual impairment and frailty holds across
281 different racial and ethnic subgroups.

282 **Conclusion**

283 In this study, we explored the genetic correlations and causal relationships between VI and frailty
284 using MR and LDSC. Our findings revealed significant genetic correlations between specific VI
285 subtypes and frailty and provided evidence of bidirectional causal relationships. Specifically, visual
286 disturbances, other types of cataracts, diabetic retinopathy, and age-related macular degeneration
287 increased the risk of frailty, while frailty also heightened susceptibility to VI.

288 To summarize, this work provides evidence of genetic connections and causal effects between frailty
289 and VI. Considering the fact that frailty and VI are often curable and interconnected illnesses, timely
290 screening of elderly persons for VI and frailty can enhance their quality of life and minimize the
291 course of disease and disability. Moreover, it is important to consider visual function as a potential
292 risk factor for frailty and to regularly assess it in the context of geriatric care. Future research should
293 stratify analyses by incorporating multiethnic cohorts, leveraging larger datasets with enhanced
294 statistical power, and employing advanced methodological techniques. A more thorough
295 investigation of the mechanisms of infirmity is crucial to discern the key pathways between visual
296 impairment and infirmity.

297 **Declarations**

298 **Ethics statement:** We derived all of the data for our MR study from summary figures that were
299 previously released to the public. Thus, the investigation can proceed without obtaining ethical
300 clearance or patient consent.

301 **Consent for publication:** Not applicable

302 **Availability of data and materials:** The corresponding author can provide the datasets used and/or
303 analyzed in this study upon reasonable request.

304 **Competing interests:** According to the writers, they have no conflicting interests.

305 **Funding:** No funding.

306 **Authors' contributions:** ZD: preparing the first draft, method, conception, formal analysis,
307 gathering of data, and visualization; ZDBY: visualization, and written data curation; TSH:
308 monitoring, and writing evaluation. All of the authors who contributed to the manuscript's final draft
309 granted their consent.

310 **Acknowledgements:** The authors would like to thank all those who provided the open access
311 datasets used in the study, including the FinnGen Consortium.


312 **References**

- 313 1. Gonzales-Turín JM, Rodríguez-Laso Á, Carnicero JA, García-García FJ, Rodríguez-Mañas L.
314 Relationship between self-reported visual impairment and worsening frailty transition states in older
315 people: a longitudinal study. *Aging Clin Exp Res* 2021;33:2491-2498.
- 316 2. Swenor BK, Simonsick EM, Ferrucci L, *et al.* Visual impairment and incident mobility
317 limitations: the health, aging and body composition study. *J Am Geriatr Soc* 2015;63:46-54.
- 318 3. Swenor BK, Muñoz B, West SK. A longitudinal study of the association between visual
319 impairment and mobility performance in older adults: the salisbury eye evaluation study. *Am J*
320 *Epidemiol* 2014;179:313-322.
- 321 4. Ong SY, Ikram MK, Haaland BA, *et al.* Myopia and cognitive dysfunction: the singapore malay
322 eye study. *Invest Ophthalmol Vis Sci* 2013;54:799-803.

- 323 5. Christ SL, Zheng DD, Swenor BK, *et al.* Longitudinal relationships among visual acuity, daily
324 functional status, and mortality: the Salisbury Eye Evaluation Study. *JAMA Ophthalmol*
325 2014;132:1400-1406.
- 326 6. Swenor BK, Lee MJ, Tian J, Varadaraj V, Bandeen-Roche K. Visual Impairment and Frailty:
327 Examining an Understudied Relationship. *J Gerontol A Biol Sci Med Sci* 2020;75:596-602.
- 328 7. Flaxman SR, Bourne RRA, Resnikoff S, *et al.* Global causes of blindness and distance vision
329 impairment 1990-2020: a systematic review and meta-analysis. *Lancet Glob Health* 2017;5:e1221-
330 e1234.
- 331 8. Xue QL. The frailty syndrome: definition and natural history. *Clin Geriatr Med* 2011;27:1-15.
- 332 9. Lan X, Li H, Wang Z, Chen Y. Frailty as a predictor of future falls in hospitalized patients: A
333 systematic review and meta-analysis. *Geriatr Nurs* 2020;41:69-74.
- 334 10. Yamada M, Arai H. Social Frailty Predicts Incident Disability and Mortality Among
335 Community-Dwelling Japanese Older Adults. *J Am Med Dir Assoc* 2018;19:1099-1103.
- 336 11. Chang SF, Lin HC, Cheng CL. The Relationship of Frailty and Hospitalization Among Older
337 People: Evidence From a Meta-Analysis. *J Nurs Scholarsh* 2018;50:383-391.
- 338 12. O'Caomh R, Sezgin D, O'Donovan MR, *et al.* Prevalence of frailty in 62 countries across the
339 world: a systematic review and meta-analysis of population-level studies. *Age Ageing* 2021;50:96-
340 104.
- 341 13. Chi J, Chen F, Zhang J, *et al.* Impacts of frailty on health care costs among community-dwelling
342 older adults: A meta-analysis of cohort studies. *Arch Gerontol Geriatr* 2021;94:104344.
- 343 14. Klein BE, Klein R, Knudtson MD, Lee KE. Relationship of measures of frailty to visual
344 function: the Beaver Dam Eye Study. *Trans Am Ophthalmol Soc* 2003;101:191-196; discussion 196-
345 199.
- 346 15. Liljas AEM, Carvalho LA, Papachristou E, *et al.* Self-reported vision impairment and incident
347 prefrailty and frailty in English community-dwelling older adults: findings from a 4-year follow-up
348 study. *J Epidemiol Community Health* 2017;71:1053-1058.
- 349 16. Varadaraj V, Lee MJ, Tian J, *et al.* Near Vision Impairment and Frailty: Evidence of an
350 Association. *Am J Ophthalmol* 2019;208:234-241.
- 351 17. Amir NN, Kamaruzzaman SB, Effendi-Tenang I, *et al.* Contrast sensitivity is associated with
352 frailty. *Eur Geriatr Med* 2021;12:313-319.
- 353 18. Soler V, Sourdet S, Balardy L, *et al.* Visual Impairment Screening at the Geriatric Frailty Clinic
354 for Assessment of Frailty and Prevention of Disability at the G erontop ole. *J Nutr Health Aging*
355 2016;20:870-877.
- 356 19. Bulik-Sullivan B, Finucane HK, Anttila V, *et al.* An atlas of genetic correlations across human
357 diseases and traits. *Nat Genet* 2015;47:1236-1241.
- 358 20. Zhou J, Li Y, Lin Y, *et al.* The genetic causal association between hip or knee osteoarthritis and
359 frailty: a two-sample Mendelian randomization analysis. *Arch Med Sci* 2024;20:938-946.
- 360 21. Sekula P, Del Greco MF, Pattaro C, K ottgen A. Mendelian Randomization as an Approach to
361 Assess Causality Using Observational Data. *J Am Soc Nephrol* 2016;27:3253-3265.

- 362 22. Davey Smith G, Holmes MV, Davies NM, Ebrahim S. Mendel's laws, Mendelian randomization
363 and causal inference in observational data: substantive and nomenclatural issues. *Eur J Epidemiol*
364 2020;35:99-111.
- 365 23. Skrivankova VW, Richmond RC, Woolf BAR, *et al.* Strengthening the Reporting of
366 Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR
367 Statement. *Jama* 2021;326:1614-1621.
- 368 24. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in
369 epidemiological studies. *Hum Mol Genet* 2014;23:R89-98.
- 370 25. Lawlor DA. Commentary: Two-sample Mendelian randomization: opportunities and challenges.
371 *Int J Epidemiol* 2016;45:908-915.
- 372 26. Kurki MI, Karjalainen J, Palta P, *et al.* FinnGen provides genetic insights from a well-
373 phenotyped isolated population. *Nature* 2023;613:508-518.
- 374 27. Atkins JL, Jylhävä J, Pedersen NL, *et al.* A genome-wide association study of the frailty index
375 highlights brain pathways in ageing. *Aging Cell* 2021;20:e13459.
- 376 28. Ye Y, Noche RB, Szejko N, *et al.* A genome-wide association study of frailty identifies
377 significant genetic correlation with neuropsychiatric, cardiovascular, and inflammation pathways.
378 *Geroscience* 2023;45:2511-2523.
- 379 29. Hoogendijk EO, Afilalo J, Ensrud KE, *et al.* Frailty: implications for clinical practice and public
380 health. *Lancet* 2019;394:1365-1375.
- 381 30. Goławski M, Lejawa M, Banach M, *et al.* Association between Lp(a) and T2D: a Mendelian
382 randomization study. *Arch Med Sci* 2024;20:1002-1005.
- 383 31. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for
384 Mendelian randomization studies using multiple genetic variants. *Int J Epidemiol* 2011;40:740-752.
- 385 32. Burgess S, Davey Smith G, Davies NM, *et al.* Guidelines for performing Mendelian
386 randomization investigations: update for summer 2023. *Wellcome Open Res* 2019;4:186.
- 387 33. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian
388 randomisation studies with summary data and a continuous outcome. *Stat Med* 2015;34:2926-2940.
- 389 34. Bowden J, Del Greco MF, Minelli C, *et al.* A framework for the investigation of pleiotropy in
390 two-sample summary data Mendelian randomization. *Stat Med* 2017;36:1783-1802.
- 391 35. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect
392 estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512-525.
- 393 36. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal
394 relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet*
395 2018;50:693-698.
- 396 37. Bowden J, Spiller W, Del Greco MF, *et al.* Improving the visualization, interpretation and
397 analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial
398 regression. *Int J Epidemiol* 2018;47:2100.
- 399 38. Bowden J, Del Greco MF, Minelli C, *et al.* Improving the accuracy of two-sample summary-data
400 Mendelian randomization: moving beyond the NOME assumption. *Int J Epidemiol* 2019;48:728-742.

- 401 39. Ni G, Moser G, Wray NR, Lee SH. Estimation of Genetic Correlation via Linkage
402 Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. *Am J Hum Genet*
403 2018;102:1185-1194.
- 404 40. Bulik-Sullivan BK, Loh PR, Finucane HK, *et al.* LD Score regression distinguishes confounding
405 from polygenicity in genome-wide association studies. *Nat Genet* 2015;47:291-295.
- 406 41. Carter CS, Hofer T, Seo AY, Leeuwenburgh C. Molecular mechanisms of life- and health-span
407 extension: role of calorie restriction and exercise intervention. *Appl Physiol Nutr Metab*
408 2007;32:954-966.
- 409 42. Masuda T, Shimazawa M, Hara H. Retinal Diseases Associated with Oxidative Stress and the
410 Effects of a Free Radical Scavenger (Edaravone). *Oxid Med Cell Longev* 2017;2017:9208489.
- 411 43. Pinazo-Durán MD, Gallego-Pinazo R, García-Medina JJ, *et al.* Oxidative stress and its
412 downstream signaling in aging eyes. *Clin Interv Aging* 2014;9:637-652.
- 413 44. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma.
414 *J Glaucoma* 2009;18:93-100.
- 415 45. Smith L, López-Sánchez GF, Jacob L, *et al.* Objectively measured far vision impairment and
416 sarcopenia among adults aged ≥ 65 years from six low- and middle-income countries. *Aging Clin*
417 *Exp Res* 2021;33:2995-3003.
- 418 46. Ho VWT, Chen C, Merchant RA. Cumulative Effect of Visual Impairment, Multimorbidity, and
419 Frailty on Intrinsic Capacity in Community-Dwelling Older Adults. *J Aging Health* 2020;32:670-
420 676.
- 421 47. Laudisio A, Navarini L, Margiotta DPE, *et al.* The Association of Olfactory Dysfunction, Frailty,
422 and Mortality Is Mediated by Inflammation: Results from the InCHIANTI Study. *J Immunol Res*
423 2019;2019:3128231.
- 424 48. Liljas AE, Wannamethee SG, Whincup PH, *et al.* Socio-demographic characteristics, lifestyle
425 factors and burden of morbidity associated with self-reported hearing and vision impairments in older
426 British community-dwelling men: a cross-sectional study. *J Public Health (Oxf)* 2016;38:e21-28.
- 427 49. Dai Z, Wu Y, Chen J, Huang S, Zheng H. Assessment of relationships between frailty and
428 chronic pain: a bidirectional two-sample Mendelian randomisation study. *Age Ageing* 2024;53.
- 429 50. Xin M, Wang W, Zhou M, *et al.* Genetically-predicted effects of lifestyle factors on frailty:
430 Evidence from Mendelian randomization study. *Arch Gerontol Geriatr* 2025;129:105662.
- 431




Preprint

Exposure	Outcome	nSNP	OR	Pval
Visual disturbances	Frailty index	19	1.04(1.01-1.07)	1.01E-02
	Fried Frailty Score	18	1.00(0.99-1.02)	6.94E-01
Glaucoma	Frailty index	38	1.01(0.99-1.02)	3.91E-01
	Fried Frailty Score	43	1.00(1.00-1.01)	2.60E-01
Senile cataract	Frailty index	33	1.02(1.00-1.05)	5.60E-02
	Fried Frailty Score	30	1.01(1.00-1.02)	1.22E-01
Other cataract	Frailty index	14	1.03(1.00-1.05)	3.24E-02
	Fried Frailty Score	14	1.01(1.00-1.03)	2.70E-02
Diabetic retinopathy	Frailty index	6	1.04(1.03-1.06)	3.14E-08
	Fried Frailty Score	6	1.02(1.01-1.02)	1.19E-05
Age-related macular degeneration	Frailty index	22	1.01(1.00-1.02)	1.31E-01
	Fried Frailty Score	19	1.01(1.00-1.01)	2.51E-02
Hypermetropia	Frailty index	8	1.00(0.99-1.02)	7.30E-01
	Fried Frailty Score	8	1.00(0.99-1.01)	7.96E-01
Myopia	Frailty index	18	1.01(0.99-1.02)	4.37E-01
	Fried Frailty Score	16	1.00(0.99-1.01)	7.75E-01

Causal effect of VI on frailty.




Preprint



Preprint

Exposure	Outcome	nSNP	OR	Pval
Frailty index	Visual disturbances	13	1.60(1.19-2.15)	1.65E-03
Fried Frailty Score		24	1.60(1.10-2.34)	1.50E-02
Frailty index	Glaucoma	11	1.22(0.84-1.75)	2.95E-01
Fried Frailty Score		21	1.23(0.80-1.91)	3.50E-01
Frailty index	Senile cataract	12	1.17(0.96-1.44)	1.27E-01
Fried Frailty Score		20	1.06(0.80-1.39)	6.96E-01
Frailty index	Other cataract	13	1.13(0.84-1.51)	4.34E-01
Fried Frailty Score		22	1.33(0.89-1.97)	1.59E-01
Frailty index	Diabetic retinopathy	13	0.89(0.60-1.32)	5.62E-01
Fried Frailty Score		22	0.72(0.43-1.22)	2.23E-01
Frailty index	Age-related macular degeneration	11	0.83(0.53-1.31)	4.19E-01
Fried Frailty Score		24	1.34(0.80-2.27)	2.69E-01
Frailty index	Hypermetropia	13	1.28(0.57-2.89)	5.49E-01
Fried Frailty Score		24	1.77(0.60-5.18)	2.98E-01
Frailty index	Myopia	14	0.91(0.53-1.54)	7.13E-01
Fried Frailty Score		21	0.56(0.25-1.27)	1.63E-01

Causal effect of frailty on VI.



Preprint